Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Assertio (ASRT) Gains But Lags Market: What You Should Know

Published 02/04/2020, 05:45 AM
Updated 07/09/2023, 06:31 AM
US500
-
DJI
-

In the latest trading session, Assertio (ASRT) closed at $1.05, marking a +0.48% move from the previous day. This move lagged the S&P 500's daily gain of 1.5%. Elsewhere, the Dow gained 1.44%, while the tech-heavy Nasdaq added 2.1%.

Prior to today's trading, shares of the drugmaker had lost 3.24% over the past month. This has lagged the Medical sector's gain of 0.34% and the S&P 500's gain of 0.54% in that time.

Wall Street will be looking for positivity from ASRT as it approaches its next earnings report date. The company is expected to report EPS of $0.14, down 53.33% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $50.30 million, up 18.07% from the prior-year quarter.

Investors should also note any recent changes to analyst estimates for ASRT. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ASRT is currently a Zacks Rank #3 (Hold).

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Valuation is also important, so investors should note that ASRT has a Forward P/E ratio of 1.49 right now. This valuation marks a discount compared to its industry's average Forward P/E of 14.74.

Meanwhile, ASRT's PEG ratio is currently 0.07. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Drugs stocks are, on average, holding a PEG ratio of 1.15 based on yesterday's closing prices.

The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 115, which puts it in the top 46% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.



ASSERTIO THERAPEUTICS, INC (ASRT): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.